• Combination Therapy

    Regenetek’s Combination Stem Cell and Vascular Therapy

    read more
  • Regenerative Medicine

    ‎The Most Current Information Available from Leading Scientists and Clinical Trials World-wide

    read more
  • Patient Registry Software

    Application of Technology to Make Any Size of Study Self-Managing and Affordable

    read more
  • Neurodegenerative Disorders

    The Latest Updates on Diseases Treatable Through Regenerative Medicine

    read more
  • Topical
    Commentary

    Opinions from Regenetek and Leading Authorities in Regenerative Medicine

    read more

University of Winnipeg Approves Study

Separate Research Initiative through University of Winnipeg Confirms Efficacy of Combination Therapy

The University of Winnipeg has approved the framework for a study of MS patients treated through the Regenetek Research Combination Therapy protocol. Clinicians at the University of Winnipeg have been impressed enough by observing and evaluating patients treated by this method to conclude that functional recovery is possible in many if not all cases. To this end, the Physiotherapy Department under Dr. Glen Bergeron has been approved by the University for a Research Study aimed at allowing patients to recover more efficiently and effectively through application of newly conceived and applied rehabilitation strategies. Dr. Bergeron will be the Principle Investigator. This is recognition by a major Canadian university that patients with a chronic, long-term neuromuscular disease, even severely atrophic patients, can be returned to function. It is also certain corroboration that the Combination Therapy is effective, at least in the intermediate term. Regarding the sequential therapy with stem cells under study by Regenetek Research, it is not yet known whether patients will need more than one stem cell treatment, but to date, two years into the study, no patient has needed a second intervention and all patients continue to recover while showing no signs of their disease symptoms.

The results indicated by preliminary study data and the observation and evaluation of the subjects in the study demonstrate the reliability of improved outcomes for patients having been treated in the Regenetek study. Because of this, there is now a further need to advance new physiotherapeutic strategies for returning patients to functional health once they have had the cellular therapy since many have been paralyzed or non-ambulatory for many years resulting in postural stress syndrome (PSS), which is deformity due to the abnormal shortening of ligaments and muscles.

MS Patients who have taken physiotherapy after their cellular therapies are clearly demonstrating a natural increase in strength, endurance, balance and agility. This is at odds with the conventional physiotherapeutic management of MS patients because rehabilitation strategies have always been defined by the patient’s expected deterioration of function. In cases where patients have been stricken with advanced MS, physiotherapists may be influenced by their obvious deformities due to progressive neuromuscular disease, including deficits such as pelvic obliquity, split hand, and scoliosis to name a few. With the significant improvement in functional deficits, physiotherapists that manage these cases may not recognize the possibility of full return to function because this phenomenon has not been described in the medical literature prior to the Regenetek Study. This has now opened the possibility of considering whether or not a more active recovery program using a different restorative rehabilitation philosophy would lead to increased functional capacity beyond using only adaptive strategies. However, in all patients to date, even without rehabilitation, stem cell therapy has allowed patients to not only reduce or eliminate active symptoms of their neurological disease, but in many cases, regain much of their ability to perform activities of daily living (ADL) and improve their personal independence.

Formal approval by the university will be formally announced in early 2014.

Written by Doug Broeska

Doug Broeska is a PhD Medical Researcher and CEO of Regenetek Inc, a Canadian Biotech Research firm working with several hospitals and clinics world-wide to develop medical procedural protocols for neurodegenerative disease management.